Evidence map›Paper›PMID 32678844›Full record

ArticlePloS one2020

Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses.

Michael G Berg, Ana Olivo, Kenn Forberg, Barbara J Harris, Julie Yamaguchi, Rachel Shirazi, Yael Gozlan, Silvia Sauleda, Lazare Kaptue, Mary A Rodgers and 2 more

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. First Evidence of Spillover ofTransboundary and emerging diseases · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Characterization of Dengue Virus Serotype 2 Cosmopolitan Genotype Circulating in Colombia.The American journal of tropical medicine and hygiene · 2023
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michael G BergInfectious Diseases Research, Abbott Diagnostics, Abbott Park, Illinois, United States of America.ORCID 0000-0003-0233-5819
Ana OlivoInfectious Diseases Research, Abbott Diagnostics, Abbott Park, Illinois, United States of America.
Kenn ForbergInfectious Diseases Research, Abbott Diagnostics, Abbott Park, Illinois, United States of America.
Barbara J HarrisInfectious Diseases Research, Abbott Diagnostics, Abbott Park, Illinois, United States of America.
Julie YamaguchiInfectious Diseases Research, Abbott Diagnostics, Abbott Park, Illinois, United States of America.
Rachel ShiraziCentral Virology Laboratory, National HIV and Viral Hepatitis Reference Center, Public Health Services, Ministry of Health, Tel-Hashomer, Ramat-Gan, Israel.
Yael GozlanCentral Virology Laboratory, National HIV and Viral Hepatitis Reference Center, Public Health Services, Ministry of Health, Tel-Hashomer, Ramat-Gan, Israel.
Silvia SauledaTransfusion Safety Laboratory, Banc de Sang i Teixits, Servei Català de la Salut, Barcelona, Spain.
Lazare KaptueUniversité des Montagnes, Bangangté, Cameroon.
Mary A RodgersInfectious Diseases Research, Abbott Diagnostics, Abbott Park, Illinois, United States of America.
Orna MorCentral Virology Laboratory, National HIV and Viral Hepatitis Reference Center, Public Health Services, Ministry of Health, Tel-Hashomer, Ramat-Gan, Israel.
Gavin A ClohertyInfectious Diseases Research, Abbott Diagnostics, Abbott Park, Illinois, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Defining genetic diversity of viral infections directly from patient specimens is the ultimate goal of surveillance. Simple tools that can provide full-length sequence information on blood borne viral hepatitis viruses: hepatitis C, hepatitis B and hepatitis D viruses (HCV, HBV and HDV) remain elusive. Here, an unbiased metagenomic next generation sequencing approach (mNGS) was used for molecular characterization of HCV infections (n = 99) from Israel which yielded full-length HCV sequences in 89% of samples, with 7 partial sequences sufficient for classification. HCV genotypes were primarily 1b (68%) and 1a (19%), with minor representation of genotypes 2c (1%) and 3a (8%). HBV/HDV coinfections were characterized by suppressed HBV viral loads, resulting in sparse mNGS coverage. A probe-based enrichment approach (xGen) aiming to increase HBV and HDV coverage was validated on a panel of diverse genotypes, geography and titers. The method extended HBV genome coverage a median 61% (range 8-84%) and provided orders of magnitude boosts in reads and sequence depth for both viruses. When HBV-xGen was applied to Israeli samples, coverage was improved by 28-73% in 4 samples and identified HBV genotype A1, A2, D1 specimens and a dual B/D infection. Abundant HDV reads in mNGS libraries yielded 18/26 (69%) full genomes and 8 partial sequences, with HDV-xGen only providing minimal extension (3-11%) of what were all genotype 1 genomes. Advanced molecular approaches coupled to virus-specific capture probes promise to enhance surveillance of viral infections and aid in monitoring the spread of local subtypes.

Indexed as

High-Throughput Nucleotide SequencingMetagenomicsBloodCohort StudiesGenotypeHepatitis VirusesHumans

Identifiers

PMID32678844
PMCPMC7367454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.